Erythropoiesis-stimulating agents in gynecological malignancies: A study-level meta-analysis

Highlights • Gynecological cancers are the one at highest risk of anemia. • Data on erythropoiesis-stimulating agents (ESAs) benefit and risks are discordant. • We found significant reduction in transfusion rates. • We found no detrimental effect on overall mortality and failures disease.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Critical reviews in oncology/hematology 2016-03, Vol.99, p.123-128
Hauptverfasser:	Marchetti, C, De Felice, F, Palaia, I, Musio, D, Muzii, L, Tombolini, V, Benedetti Panici, P
Format:	Artikel
Sprache:	eng
Schlagworte:	Anemia Anemia - drug therapy Anemia - etiology Chemotherapy Disease Progression Erythropoiesis - drug effects Erythropoiesis-stimulating agents Gynecological cancer Hematinics - therapeutic use Hematology, Oncology and Palliative Medicine Humans Mortality Neoplasms - complications Neoplasms - therapy Transfusion
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Gynecological cancers are the one at highest risk of anemia. • Data on erythropoiesis-stimulating agents (ESAs) benefit and risks are discordant. • We found significant reduction in transfusion rates. • We found no detrimental effect on overall mortality and failures disease.
ISSN:	1040-8428 1879-0461
DOI:	10.1016/j.critrevonc.2015.12.013